- Home
- PPT vs CCCC Comparison
PPT vs CCCC Comparison
Compare PPT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPT
- CCCC
- Stock Information
- Founded
- PPT 1988
- CCCC 2015
- Country
- PPT United States
- CCCC United States
- Employees
- PPT N/A
- CCCC N/A
- Industry
- PPT Finance Companies
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- PPT Finance
- CCCC Health Care
- Exchange
- PPT Nasdaq
- CCCC Nasdaq
- Market Cap
- PPT 338.4M
- CCCC 396.0M
- IPO Year
- PPT N/A
- CCCC 2020
- Fundamental
- Price
- PPT $3.56
- CCCC $3.86
- Analyst Decision
- PPT
- CCCC Buy
- Analyst Count
- PPT 0
- CCCC 6
- Target Price
- PPT N/A
- CCCC $10.67
- AVG Volume (30 Days)
- PPT 156.1K
- CCCC 2.0M
- Earning Date
- PPT 01-01-0001
- CCCC 02-20-2025
- Dividend Yield
- PPT 8.84%
- CCCC N/A
- EPS Growth
- PPT N/A
- CCCC N/A
- EPS
- PPT N/A
- CCCC N/A
- Revenue
- PPT N/A
- CCCC $33,668,000.00
- Revenue This Year
- PPT N/A
- CCCC $75.79
- Revenue Next Year
- PPT N/A
- CCCC N/A
- P/E Ratio
- PPT N/A
- CCCC N/A
- Revenue Growth
- PPT N/A
- CCCC 65.45
- 52 Week Low
- PPT $3.25
- CCCC $3.38
- 52 Week High
- PPT $3.72
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- PPT 50.31
- CCCC 48.86
- Support Level
- PPT $3.53
- CCCC $3.79
- Resistance Level
- PPT $3.58
- CCCC $4.03
- Average True Range (ATR)
- PPT 0.03
- CCCC 0.26
- MACD
- PPT 0.00
- CCCC 0.05
- Stochastic Oscillator
- PPT 55.00
- CCCC 62.50
About PPT Putnam Premier Income Trust
Putnam Premier Income Trust is a Massachusetts business trust operating as a non-diversified closed-end management investment company. The fund is currently operating as a diversified fund. Its investment objective is to seek high current income consistent with the preservation of capital by allocating its investments to the U.S. government sector.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.